| 摘要 |
<p>The invention relates to the use of one or more of protein myoferlin, protein latent-transforming growth factor beta binding protein2, protein transforming growth factor beta induced protein ig-h3, protein asporin,protein tenascin, protein periostin, protein galectin,protein fibronectin, protein prolargin, protein protein-glutamine gamma-glutamyl transferase 2, protein agrin, protein adipocyte enhancer-binding protein 1, protein annexin A6, protein laminin alpha-2 subunit, proteinlaminin subunit alpha-4, protein mimecan, protein Ras-related protein Rap-2b,protein collagen alpha-1 (XIV) chain, protein collagen alpha-3 (VI) chain, protein latent-transforming growth factor beta binding protein1, protein V type proton ATPase catalytic subunit A, protein laminin alpha-4 and protein transmembrane protein 62 as a biomarker for pancreatic cancer, or a predisposition thereto. The invention also relates to ligands directed to the above-mentioned biomarkers, for use in the therapeutic and/or prophylactic treatment of a pancreatic cancer.</p> |
